A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322
NCT ID: NCT01686711
Last Updated: 2023-08-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
207 participants
INTERVENTIONAL
2012-09-30
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Combination Therapy With SYR-322
NCT01521962
Long-term Study of SYR-472
NCT01431807
Double-blind Comparative Study of SYR-472
NCT01632007
Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy
NCT02068443
A Phase 4, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 4, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes
NCT02324569
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PARALLEL
TREATMENT
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SYR-322 25 mg , AD-4833 15 mg
AD-4833 15 mg
SYR-322 25 mg , AD-4833 30 mg
AD-4833 30 mg
SYR-322 25 mg , AD-4833 placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AD-4833 15 mg
AD-4833 30 mg
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Those who can sign and date a written, informed consent form prior to the initiation of any study procedures.
Exclusion Criteria
* Others who are assessed to be ineligible for the study by the investigator or subinvestigator.
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Study Director
Role: STUDY_DIRECTOR
Takeda (Note: This product was divested to Teijin Pharma Limited in 2023)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hirosaki-shi, Aomori, Japan
Kisaratsu-shi, Chiba, Japan
Matsuyama, Ehime, Japan
Fukuoka, Fukuoka, Japan
Kitakyushu-shi, Fukuoka, Japan
Kurume-shi, Fukuoka, Japan
Fukuyama-shi, Hiroshima, Japan
Hiroshima, Hiroshima, Japan
Sapporo, Hokkaido, Japan
Koga-shi, Ibaraki, Japan
Yokohama, Kanagawa, Japan
Kumamoto, Kumamoto, Japan
Miyazaki, Miyazaki, Japan
Suita-shi, Osaka, Japan
Koshigaya-shi, Saitama, Japan
Ōtsu, Shiga, Japan
Chiyoda-ku, Tokyo, Japan
Chuo-ku, Tokyo, Japan
Itabashi-ku, Tokyo, Japan
Meguro-ku, Tokyo, Japan
Minato-ku, Tokyo, Japan
Ohta-ku, Tokyo, Japan
Shinjuku-ku, Tokyo, Japan
Toyama, Toyama, Japan
Shimonoseki-shi, Yamaguchi, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1132-3209
Identifier Type: REGISTRY
Identifier Source: secondary_id
JapicCTI-121916
Identifier Type: REGISTRY
Identifier Source: secondary_id
SYR-322-4833/CCT-901
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.